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Preventive cardiology encompasses the whole spectrum of cardiovascular disease (CVD) prevention, at individual and population level, through
all stages of life. This includes promotion of cardiovascular (CV) health, management of individuals at risk of developing CVD, and management
of patients with established CVD, through interdisciplinary care in different settings. Preventive cardiology addresses all aspects of CV health in
the context of the social determinants of health, including physical activity, exercise, sports, nutrition, weight management, smoking cessation,
psychosocial factors and behavioural change, environmental, genetic and biological risk factors, and CV protective medications.
This is the first European Core Curriculum for Preventive Cardiology, which will help to standardize, structure, deliver, and evaluate train-
ing in preventive cardiology across Europe. It will be the basis for dedicated fellowship programmes and a European Society of Preventive
Cardiology (EAPC) subspecialty certification for cardiologists, with the intention to improve quality and outcome in CVD prevention.
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Preventive cardiology encompasses the whole spectrum of cardio-
vascular disease (CVD) prevention, at individual and population level,
through all stages of life.
This includes promotion of cardiovascular (CV) health, manage-
ment of individuals at risk of developing CVD, and management of
patients with established CVD, through interdisciplinary care in dif-
ferent settings.
Preventive cardiology addresses all aspects of CV health in the
context of the social determinants of health, including physical
activity, exercise, sports, nutrition, weight management, smoking ces-
sation, psychosocial factors and behavioural change, environmental,
genetic and biological risk factors, and CV protective medications.
Preventive cardiology—towards a
sub-specialty of cardiology
Scientific advances have led to a substantial decline of death from CVD
over the last decades.1 However, CVD morbidity remains high and
CVD are still the most common cause of death across European
Society of Cardiology (ESC) member countries.2 While positive trends
have been observed for medical management of arterial hypertension
and dyslipidaemias, the prevalence of obesity has more than doubled
and the prevalence of diabetes mellitus has tripled in Europe.2 More
recent declines in the age-standardized incidence of CVD across ESC
member countries have been small or absent.2 The incidence of
CVD’s major components, ischaemic heart disease, and stroke, have
both shown a downward trend but changes in prevalence have been
small.2 In a European Heart Network study, CVD was estimated to
































































































cost the European Union economy 210 billion Euro a year in 2015, of
which 53% (111 billion Euro) was due to healthcare costs.2
The cardiology community has started a transition from predomin-
antly treatment to prevention of CVD.3 A large body of scientific evi-
dence has been generated and appropriate guidelines and position
papers are available in the four domains of preventive cardiology:
Population science and public health,4,5 primary prevention and risk
factor management,3,6–8 secondary prevention and cardiovascular re-
habilitation,3,9–14 and sports cardiology and exercise.15–21 The
European Association for Preventive Cardiology (EAPC) has recently
started centre accreditation in these domains to standardize and op-
timize care.22
Historically, CV prevention has been classified into primordial pre-
vention (population-based measures to prevent risk factor develop-
ment), primary prevention (management of individuals without
clinically manifest disease but at risk of developing CVD, with the aim of
delaying or preventing the onset of disease), and secondary prevention
(focusing on people with established CVD). While preventive measures
indeed differ in various ways for these three categories, this Task Force
also acknowledges that CV risk is a continuum and that several meas-
ures to enhance CV health are applicable across the spectrum of CV
prevention. Moreover, the distinction between primary and secondary
prevention, albeit well-established, may in certain occasions be artificial;
while people with subclinical disease (e.g. evidence of advanced athero-
sclerosis by imaging, but not yet with clinically manifest CVD) would
formally belong to ‘primary prevention’, they often qualify for interven-
tions applicable to the ‘secondary prevention’ setting.
Both in high-, middle-, and low-income countries, nine potentially
modifiable health behaviours and CV risk factors account for most of the
population attributable risk of myocardial infarction and stroke in both
sexes and at all ages.23,24 Smoking, physical inactivity, unhealthy nutrition
patterns, obesity, psychosocial factors, diabetes mellitus, dyslipidaemias,
and arterial hypertension are key targets for lifestyle interventions, and
optimization of medical therapy. In addition, biomarkers and genetics
risk scores25 have the potential to further characterize individual CVD
risk profiles. Beyond traditional risk factors, other drivers of residual CV
risk have come to the forefront, including inflammatory, pro-thrombotic,
and metabolic pathways that contribute to recurrent events and are
often unrecognized and not addressed in clinical practice.26
The increasing rates of obesity and diabetes, the suboptimal life-
style management and implementation of guideline-directed medical
therapy in secondary prevention of CVD,27 and the gaps in evidence
highlight the need for further investment in preventive cardiology.
The level of profound knowledge, specialized skills, and committed
attitudes goes beyond core cardiology training and justifies sub-
specialty training. In addition to expertise in a single CVD risk factor
(e.g. diagnosis and management of dyslipidaemias), competencies are
required to evaluate and manage single risk factors in the individual’s
overall risk profile, take environmental, genetic, lifestyle and psycho-
social aspects into account, integrate guideline-directed medical ther-
apy, and propose a holistic management plan including attainable and
realistic short-, mid-, and long-term goals. Motivational interviewing
skills are required to gain the patient’s willingness to adhere to life-
style changes and guideline-directed medical therapies in order to
reach these goals. Leadership and communication skills are required
to cooperate with interdisciplinary healthcare teams and other
partners. Beside classical patient groups (individuals with CV risk fac-
tors, patients after acute coronary syndromes, or with chronic cor-
onary syndromes, heart failure, implantable devices, peripheral artery
disease), preventive cardiology can contribute to CV risk factor man-
agement in different patient populations, e.g. diabetes,6 atrial fibrilla-
tion,28 and cancer.29,30 Moreover, specific aspects of sports
cardiology will have to be covered (Figure 1).
As a sub-specialty, a broader perspective of CVD prevention is ne-
cessary. Pregnancy, infancy, adolescence, early adulthood, adult and
elderly life are distinct periods with individual potential opportunities
for prevention. Pre-conception and pregnancy are important phases
for the next generation, while post-mortem autopsy may reveal rele-
vant information for living relatives (Figure 2).31 Precision medicine
and digital health start to play a role in CVD prevention and have the
potential to improve phenotyping of patients for more personalized
and tailored therapies, and better outcomes.32,33 Emerging concepts
inform new collaborations in the future and an expansion of the field
of preventive cardiology.
A common European core curriculum for preventive cardiology
will help to standardize, structure, deliver, and evaluate training of
cardiologists in preventive cardiology across Europe. This will be the
basis for dedicated fellowship programmes and an EAPC sub-
specialty certification, contributing to improvements of quality and
outcome in CVD prevention. Similar initiatives have been launched in
the USA.34–36 In the evolving field of preventive cardiology, the core
curriculum will have to be updated at regular intervals to include
emerging concepts and new scientific evidence.
The concept of the core
curriculum for preventive
cardiology
The changing nature of our profession and the changing environment
of healthcare has led to specific requirements in the field of cardi-
ology. In 2007, the European Board for the Specialty of Cardiology
(EBSC) published recommendations for sub-specialty accreditation
in cardiology.37 A sub-specialty is defined as a specific field of cardi-
ology, where knowledge and skills go beyond the basic requirements
of general cardiology and additional training is necessary. Sub-
specialty training should be based on a published core curriculum.37
The core curriculum should include a formal education plan intended
to bring expected learning outcomes. It should include the rationale,
aims, and objectives, expected learning outcomes, education content,
teaching and learning strategies, and assessment procedures. 37
Over the last decades, sub-specialty curricula have been devel-
oped and published by most ESC associations (Acute Cardiovascular
Care, Arrhythmias & Cardiac Pacing, Heart Failure, Cardiovascular
Imaging, Percutaneous Cardiovascular Interventions).38 In the field of
preventive cardiology, the American College of Cardiology (ACC)/
American Heart Association (AHA) published a competence and
training statement in 2009.34 More recent proposals for sports cardi-
ology qualification are available from the ACC and EAPC.16,39
This document is the first common European core curriculum for
preventive cardiology, covering all aspects of the field, including pre-
vention, rehabilitation, and sports cardiology. It should serve as a
framework for the sub-specialty qualification of cardiologists in
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Figure 1 Preventive cardiology—domains, necessary competencies, and cooperation partners. CPET, cardiopulmonary exercise testing; CV,
cardiovascular.
Figure 2 Lifelong cardiovascular disease prevention from the cradle to the grave and beyond.31
































































































preventive cardiology. The description of practical educational pro-
grammes, requirements for training centres and trainers is out of the
scope of this document, and will be addressed in future documents.
Advanced competencies in sports cardiology may be required in dedi-
cated referral centres, addressed by a specific additional curriculum.
A core curriculum task force was established in 2019, including mem-
bers of the EAPC Education Committee, the EAPC Board, and the
EAPC Young Community. A writing group, including representatives of
the four EAPC sections contributed to the drafting of the entrustable
professional activities (EPAs).40 Their views and comments were cap-
tured in an iterative process employing teleconferences, in-person dis-
cussions, an online Delphi survey, and workshops at EAPC meetings.
The document was developed in cooperation with the task force
of the ESC Core Curriculum for the Cardiologist.41 Key competen-
cies from the field of preventive cardiology are important for core
cardiology training and covered in Chapter 8 on prevention, rehabili-
tation, and sports.41 This chapter was used during the drafting pro-
cess of this document, and served as a guideline to harmonize
structure and content. The intention of this core curriculum is to de-
scribe the additional knowledge, skills, and attitudes necessary for
sub-specialty qualification in preventive cardiology. The final docu-
ment was approved by the EAPC Board in October 2020, and
reviewed by the ESC Education Committee.
1. CanMEDS roles
The Royal College of Physicians and Surgeons of Canada have pro-
duced a widely accepted standard framework of physician roles,
CanMEDS.42 This framework was built to identify and describe the
abilities physicians require to effectively meet the healthcare needs of
the people they serve (Table 1).42 The ESC has adopted the
CanMEDS roles in the ESC Core Curriculum for the Cardiologist.41
CanMEDS roles can be assessed and taught individually, and they
are all represented to a different extend in each of the EPAs of the
Core Curriculum for Preventive Cardiology as outlined in Chapters
1–5. While EPAs are proposed as the preferred method of assessing
specialty competencies, the CanMEDS roles can be viewed as generic
competencies of physicians.
In the field of preventive cardiology, physicians work in interdiscip-
linary teams and the scope of cardiovascular prevention goes beyond
patient care. Thus, the CanMEDs roles of communicator, collabor-
ator, and health advocate are of particular importance.
2. Clinical competencies
The conceptualization, organization, and administration of preventive
cardiology involves different groups of healthcare professionals. In
the context of this curriculum, we focus on the competences of the
cardiologist to administer of preventive cardiology in clinical practice.
In addition to the clinical competencies acquired during core cardi-
ology training,41 the sub-specialty of preventive cardiology requires
specific knowledge, skills and appropriate attitudes in primary pre-
vention, risk factor assessment and management, population science,
public health, secondary prevention, rehabilitation, sports cardiology,
and exercise testing and training.
The number of clinical competencies calls for assessment through-
out sub-specialty training. Within the process of continuous profes-
sional development, this may encourage continuous learning which
will continue after sub-specialist certification. To enable these goals,
the core curriculum consists of EPAs (see below). To make know-
ledge accessible, each EPA contains a detailed map linking to contem-
porary guidelines and position papers and the ESC topic list, thereby
enabling cross-linking with knowledge and training databases includ-
ing textbooks, structured and case-based learning courses, congress
programmes, and online materials.41
3. Entrustable professional activities
Trust is not only central for the relationship between trainers and
trainees, but also in the shared decision-making process between
physicians and their patients, and in the interaction with other health-
care professionals.41 An EPA is a key task of a discipline that an indi-
vidual can be trusted to perform in a given healthcare context, once
sufficient competence has been demonstrated.40 The EPA concept
allows trainers to make competency-based decisions about the level
of supervision required by trainees.40 Competency-based education
targets standardized levels of proficiency to guarantee that all learn-
ers have a sufficient level of proficiency at the completion of train-
ing.40 EPAs are not an alternative for competencies, but a means to
translate competencies into clinical practice. While competencies are
descriptors of physicians, EPAs are descriptors of work. EPAs usually
require multiple competencies in an integrative holistic nature.40
EPAs are observable and measurable and can be mapped to compe-
tencies and milestones across the entire landscape of physician activ-
ities. They can be monitored, documented, and certified.41
The American Board of Pediatrics was one of the first certifying
agencies that introduced the concept of EPAs in their revised training
guideline for the sub-specialty of paediatric cardiology in 2015.43 The
ESC has introduced EPAs in the 2020 update of the ESC Core
Curriculum for the Cardiologist, containing one chapter on preven-
tion, rehabilitation, and sports with seven EPAs.41
The nine EPAs of the EAPC Core Curriculum for Preventive
Cardiology describe the additional competencies necessary for the
sub-specialty of preventive cardiology and are grouped in chapters,
according to specific domains of preventive cardiology (Table 2).
All EAPC sections were involved in the definition of the content.
The EPA 2.2 Manage a patient with non-traditional cardiovascular risk fac-
tors, builds upon the competencies required for EPA 2.1 Manage indi-
viduals with multifactorial cardiovascular risk profiles, and the knowledge,
skills, and attitude sections emphasize additional and particularly rele-
vant aspects only. The same applies to EPA 3.2 Manage a prevention
and rehabilitation programme for a cardiovascular patient with significant
comorbidities, frailty, and/or cardiac devices, and EPA 3.1 Manage a pre-
vention and rehabilitation programme for a cardiovascular patient. The
EPA 5.1 Use cardiopulmonary exercise testing for diagnosis, risk stratifica-
tion and exercise prescription, deals with a testing modality, specific for
preventive cardiology, since independent execution and interpret-
ation is not required during core cardiology training.41 This EPA is
relevant in all domains of preventive cardiology.
All EPAs of this core curriculum share a common structure. The
clinical competence is defined in the title, followed by a description of
scope and timeframe, setting, including and excluding situations and
procedures. Relevant roles of the CanMEDS Physician Competency
Framework are mentioned.42 Knowledge, skills, and attitudes are for-
mulated as learning outcomes, and assessment tools are recom-
mended. The required level of independence is mentioned. Related
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Table 1 CanMEDS Physician Competency Framework, modified and adopted from the Royal College of Physicians
and Surgeons of Canada, with permission42
Role Description Key competencies
Medical expert As medical experts, physicians integrate all of the
CanMEDS roles, applying medical knowledge, clinical
skills, and professional values in their provision of high
quality and safe patient-centred care. Medical expert
is the central physician role in the CanMEDS frame-
work and defines the physician’s clinical scope of
practice.
• Practise medicine within their defined scope of practice and
expertise
• Perform a patient-centred clinical assessment and establish a man-
agement plan
• Plan and perform procedures and therapies for the purpose of as-
sessment and/or management
• Establish plans for ongoing care and, when appropriate, timely
consultation
• Actively contribute, as an individual and as a member of a team pro-
viding care, to the continuous improvement of healthcare quality
and patient safety
• Apply novel digital methods of diagnosis, treatment communication
and process to achieve optimal clinical outcomes
Communicator As communicators, physicians form relationships with
patients and their families that facilitate the gathering
and sharing of essential information for effective
health care.
• Establish professional therapeutic relationships with patients and
their families (in-person and virtual communication)
• Elicit and synthesize accurate and relevant information, incorporat-
ing the perspectives of patients and their families
• Share healthcare information and plans with patients and their
families
• Engage patients and their families in developing plans that reflect the
patient’s healthcare needs and goals
• Document and share written and electronic information about the
medical encounter to optimize clinical decision-making, patient
safety, confidentiality, and privacy
Collaborator As collaborators, physicians work effectively with other
healthcare professionals to provide safe, high quality,
patient-centred care.
• Work effectively with physicians and other colleagues in the health-
care professions
• Work with physicians and other colleagues in the healthcare profes-
sions to promote understanding, manage differences, and resolve
conflicts
• Hand over the care of a patient to another healthcare professional
to facilitate continuity of safe patient care
Leader As leaders, physicians engage with others to contribute
to a vision of a high-quality healthcare system and
take responsibility for the delivery of excellent patient
care through their activities as clinicians, administra-
tors, scholars, or teachers
• Contribute to the improvement of healthcare delivery in teams,
organizations, and systems
• Engage in the stewardship of healthcare resources
• Demonstrate leadership in professional practice
• Manage career planning, finances, and health human resources in a
practice
Health advocate As health advocates, physicians contribute their expert-
ise and influence as they work with communities or
patient populations to improve health. They work
with those they serve to determine and understand
needs, speak on behalf of others when required, and
support the mobilization of resources to effect
change.
• Respond to an individual patient’s health needs by advocating with
the patient within and beyond the clinical environment
• Respond to the needs of the communities or populations they serve
by advocating with them for system-level change in a socially ac-
countable manner
Scholar As scholars, physicians demonstrate a lifelong commit-
ment to excellence in practice through continuous
learning and by teaching others, evaluating evidence,
and contributing to scholarship.
• Engage in the continuous enhancement of their professional activ-
ities through ongoing learning
• Teach students, residents, the public, and other health care
professionals
• Integrate best available evidence into practice
Continued




















..ESC Guidelines and EAPC Position Papers are included as
primary sources of knowledge. Relevant topics from the ESC
topic list for each EPA are summarized in a Supplementary material
online, File.
4. Level of independence
The level of entrustment or independence for executing an EPA will
change during the training period (Table 3). At a certain time of the
training, trainees may have different levels of independence in differ-
ent EPAs.41 Given the broad spectrum of CVD prevention, sub-
specialty training is not intended to achieve level of independence of
five in all nine EPAs. For the following three EPAs, a lower level of in-
dependence is recommended.
1.1 Design, implement and evaluate preventive interventions at the
population level (level 3)
....................................................................................................................................................................................................................
Table 1 Continued
Role Description Key competencies
• Contribute to the creation and dissemination of knowledge and
practices applicable to health
Professional As professionals, physicians are committed to the health
and well-being of individual patients and society
through ethical practice, high personal standards of
behaviour, accountability to the profession and soci-
ety, physician-led regulation, and maintenance of per-
sonal health.
• Demonstrate a commitment to patients by applying best practices
and adhering to high ethical standards
• Demonstrate a commitment to society by recognizing and respond-
ing to societal expectations in health care
• Demonstrate a commitment to the profession by adhering to stand-
ards and participating in physician-led regulation
• Demonstrate a commitment to physician health and well-being to
foster optimal patient care
....................................................................................................................................................................................................................
Table 2 Comparison of Entrustable Professional Activities between the 2020 ESC Core Curriculum for the
Cardiologist and the 2021 EAPC Core Curriculum for Preventive Cardiology
Preventive cardiology
domains
ESC Core Curriculum for the Cardiologist EAPC Core Curriculum for Preventive Cardiology
Population science and public
health
• Design, implement, and evaluate preventive interventions
at the population level
Primary prevention and risk fac-
tor management
• Manage a patient with hypertension
• Manage a patient with dyslipidaemia
• Manage cardiovascular aspects in a diabetic
patient
• Manage a cardiac patient in primary prevention
• Manage individuals with multifactorial cardiovascular risk
profiles
• Manage a patient with non-traditional cardiovascular risk
factors
Secondary prevention and car-
diovascular rehabilitation
• Manage a cardiac patient in secondary prevention
• Prescribe a prevention and rehabilitation pro-
gramme for a cardiovascular patient
• Manage a prevention and rehabilitation programme for a
cardiovascular patient
• Manage a prevention and rehabilitation programme for a
cardiovascular patient with significant comorbidities,
frailty, and/or cardiac devices
• Manage a cardiovascular prevention and rehabilitation
programme for an oncology patient
Sports cardiology and exercise • Manage cardiovascular aspects in an athlete • Manage pre-participation screening in a competitive
athlete
• Manage the work-up of an athlete with suspected or
known cardiovascular disease
All • Use cardiopulmonary exercise testing for diagnosis, risk
stratification and exercise prescription










































2.2 Manage a patient with non-traditional cardiovascular risk
factors (level 4)
4.2 Manage the work-up of an athlete with suspected or
known cardiovascular disease (level 4)
5. Assessment of clinical competences
using EPA’s
One important aspect in the concept of EPAs is the assessment of
clinical competencies. EPAs provide a framework for trainers to per-
form easy, formative and repeated assessments of trainees during
their sub-specialty training, which help to adjust the trainee’s level of
independence.41 Optimally, these assessments should be integrated
into routine clinical care. The competencies of the trainees will fur-
ther increase after completing the training in line with their continu-
ous professional development. Consulting more experienced
colleagues or other experts in complex cases should not be judged
as need for supervision, but as a clinical reality in times of rapid
increasing medical knowledge. When a trainee is able to execute an
EPA in routine cases in an independent manner and to assume the
expected professional responsibilities, the highest level of independ-
ence is achieved.
Suitable tools for the assessment of EPAs depend on the nature of
the activity and are proposed in the assessment section of each EPA
(Table 4).41
Sources of knowledge in
preventive cardiology
In addition to specific guidelines and position papers provided at the
end of each EPA, the ESC has published four textbooks in the field
of preventive cardiology as additional source of comprehensive
knowledge.44
• ESC Textbook of Preventive Cardiology 2015
• ESC Handbook of Preventive Cardiology 2016
• ESC Textbook of Sports Cardiology 2019
• ESC Handbook of Cardiovascular Rehabilitation 2020
Table 3 Level of independence for a profession activ-
ity, adopted from41
Level 1 Trainee is able to observe
Level 2 Trainee is able to perform the activity under direct supervision
(proactive, supervisor in the room)
Level 3 Trainee is able to perform the activity under indirect supervi-
sion (reactive, on-demand supervision, supervisor readily
available)
Level 4 Trainee is able to perform the activity under distant supervi-
sion (reactive, supervision available remotely or post hoc)

















Table 4 Tools for the assessment of clinical compe-
tencies, adopted from the ESC Core Curriculum for the
Cardiologist41
Knowledge • Self-assessment witd multiple choice questions
(MCQs), e.g. provided after a webinar
Skills • Case-based discussions
• Direct observation of procedural skills (DOPS)
• Workplace-based assessments
• Mini clinical evaluation exercise (mini-CEX)




All public health interventions in the field of CVD prevention




Identification of potential needs of a population and preventive interventions
Review of past and ongoing community cohorts
Selection of the appropriate lifestyle and pharmacological interventions
Setting up budget, timeframe, milestones, and main outcomes for the interventions
Setting up the criteria for the evaluation of the interventions
Setting up occupational health programmes
Setting up population screening programmes (e.g. schools, workplaces)
Continued
Chapter 1: Population science and public health
1.1 Design, implement and evaluate preventive interventions at the population level



















 Identify target populations and preventive interventions, including groups currently underrepresented in clinical studies (women, older people, ethnic
minorities, migrants)
 Appraise the evidence regarding population-based approaches to prevention (e.g. epidemiology, randomized controlled trials, and cost effectiveness
studies)
 Be aware of potential stakeholders and collaborators
 Design studies to check safety and success of interventions
 Describe research methodology to collect data/run analysis/synthesize results of study outcomes/use audit tools
Skills
 Build a network of collaborators to identify and engage with key stakeholders, including policy makers, health services, healthcare professionals, aca-
demia, and members of the public
 Conduct a needs assessment to identify the population priorities based on good knowledge of the local population
 Integrate recommended interventions into existing preventive strategies on a population level
 Design the interventions
 Perform power calculations to determine sample sizes required to evaluate the interventions with confidence
 Create, validate, and implement data collection tools (questionnaires, instruments to collect clinical data)
 Evaluate statistical methods to analyse data taking into account possible biases/confounders.
 Calculate the cost-effectiveness of interventions
 Use early public involvement and engagement
 Engage communication channels to publicize the interventions
 Disseminate results to professionals, the public and politicians
 Evaluate effectiveness of implemented interventions, and recommend adjustments in preventive strategy if needed
 Mange projects appropriately
Attitudes
 Collaborate/negotiate with other stakeholders in planning of study
 Communicate to ensure that the intervention is understood by the target population, the stakeholders and politicians
 Consistently evaluate the intervention and adjust it according to the local results
Assessment tools
 Multiple choice questions (MCQs)
 Case-based discussions, entrustment-based discussions
 Multi-source feedback
 Simulation of population interventions
 Presentation and publication of results of the intervention
Level of independence
 Level 3 (perform the activity under indirect supervision. In this context, this means to contribute to design, implementation, and evaluation of preventive
interventions, and cooperate with partners from population science and public health, but not necessarily to take the lead in these type of projects)
Related ESC guidelines and EAPC position papers
 Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J 2020;41:12–85.
 Arena R, Guazzi M, Lianov L, et al. Healthy lifestyle interventions to combat noncommunicable disease-a novel nonhierarchical connectivity model for
key stakeholders: a policy statement from the American Heart Association, European Society of Cardiology, European Association for Cardiovascular
Prevention and Rehabilitation, and American College of Preventive Medicine. Eur Heart J 2015;36:2097–2109.
 Jorgensen T, Capewell S, Prescott E, et al. Population-level changes to promote cardiovascular health. Eur J Prev Cardiol 2013;20:409–421.
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Description
Scope and timeframe:
For every individual with known or suspected CV risk
From first evaluation to follow-up, as advised by the clinical condition
Setting:
Primary care setting (including nursing home care), in-patient setting, out-patient setting, emergency department, community setting, workplace
Including:
Baseline assessment, identification of single or multiple risk factors and multi-morbidity
Identification of individualized targets for CVD prevention using basic and advanced tools for investigation
Use of risk modifiers, and imaging in intermediate risk individuals
Guidance, lifestyle recommendations, guideline-directed medical therapy, referral, follow-up
Excluding:










 Discuss the epidemiology of CVD and its associated lifestyle, medical, and psychosocial risk factors
 Understand specific aspects of groups currently underrepresented in clinical studies (women, older people, ethnic minorities, migrants)
 Demonstrate an understanding of strategies for the reduction of CV risk across the life course
 Understand the concept of risk and the role of risk estimation tools in CVD prevention
 Understand the concept of precision medicine and deep phenotyping based on panomics and their current relevance for clinical decision-making
 Identify what individual/patient groups are at high risk for CVD and how they should be targeted for preventive care
 Describe the key critical success factors for delivering effective CVD prevention programmes
 Demonstrate an understanding of how the social determinants of health influence CV health and health inequalities
 List the investigations used to diagnose multifactorial risk profiles
 Demonstrate an understanding of lifestyle risk factor management, which includes smoking cessation, diet, and physical activity
 Appraise the latest evidence-based guidelines for managing individuals with multifactorial CV risk profiles
Skills
 Obtain a personal and family history
 Explore patient expectations, values, and priorities
 Perform a thorough physical examination
 Perform a comprehensive CV risk assessment using appropriate risk calculators and including additional tests, if necessary [blood tests, resting and exer-
cise electrocardiography (ECG), cardiopulmonary exercise testing (CPET), CV imaging]
 Assess CV and extracardiac comorbidities
 Interpret the results of examination and tests showing abnormal values
 Determine and compare the benefits of lifestyle interventions, pharmacology of drugs, or both for primary prevention
 Manage CV risk factors in line with level of individual risk and evidence-based guidelines and patient preference
 Assess nutritional habits and integrate into nutritional strategy
 Provide personalized lifestyle advice for smoking cessation, physical activity and exercise, nutrition and diet, stress management, and psychological health
 Participate as an interdisciplinary team member, working collaboratively with general practitioners, nurses, dietitians, physiotherapists, sports scientists,
psychologists, occupational therapists, pharmacists, and other professionals involved in CVD prevention
 Apply effective communication and motivational skills to support the patient in making positive lifestyle and behaviour modifications
 Communicate with family and social environment to provide support and enhance changes
Continued
Chapter 2: Primary prevention and risk factor management
2.1 Manage individuals with multifactorial cardiovascular risk profiles
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Continued
Attitudes
 Adopt a non-judgemental attitude regarding individual
lifestyle
 Adopt a shared decision approach by actively engaging the patient in management decisions based on individual values, preferences, and associated con-
ditions and co-morbidities
 Adopt a culture of interdisciplinary teamwork
 Recognize the importance of primary prevention in individuals and patients with multifactorial CV risk
Assessment tools
 MCQs
 Direct observation, workplace-based assessments [e.g. direct observation of procedural skills (DOPS), mini clinical evaluation exercise (mini-CEX),
fieldnotes]
 Case-based discussions, entrustment-based discussions
 Multiple consultant reports
 Multi-source feedback
Level of independence
 Level 5 (perform the activity without supervision, teach and supervise others)
Related ESC guidelines and EAPC position papers
 Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–477.
 Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Eur Heart J 2020;41:111–188.
 Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the
EASD. Eur Heart J 2020;41:255–323.
 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021–3104.
 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of
the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10
societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation
(EACPR). Eur Heart J 2016;37:2315–2381. Update 2021.
Description
Scope and timeframe:
For every individual with non-traditional CV risk factors, suitable for CVD prevention
From first presentation to follow-up, as advised by clinical condition
Setting:
Primary care setting (including nursing home care), in-patient setting, out-patient setting, emergency department, community settings, workplace
Including:
Assessment of CV risk in patients with abnormal biomarkers, cancer therapy, chronic kidney disease, chronic obstructive pulmonary disease, inflammatory
disease, congenital heart disease, migraine with aura, erectile dysfunction, preeclampsia, gestational diabetes, sleep disorders
Identification of residual CV risk and targets for CVD prevention using basic and advanced tools for investigation
Guidance, lifestyle recommendations, guideline-directed medical therapy, referral, follow-up
Excluding:










2.2 Manage a patient with non-traditional cardiovascular risk factors
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Knowledge
 List important non-traditional CV risk factors and diseases with elevated CV risk (e.g. abnormal biomarkers, cancer therapy, chronic kidney disease,
chronic obstructive pulmonary disease, congenital heart disease, inflammatory disease, migraine with aura, erectile dysfunction, preeclampsia, gestational
diabetes, sleep disorders)
 Describe the biopsychosocial spectrum of non-traditional CV risk factors and recognize their importance for CVD primary prevention
 Explain the use of investigations for and management of individuals with non-traditional CV risk factors
 Discuss the management of clinical complications of patients with non-traditional CV risk factors
 Outline proper laboratory testing or referral/collaboration with other specialists, in order to assess the CV risk and plan a personal health strategy
Skills
 Obtain a relevant history
 Explore patient expectations, values, and priorities
 Evaluate non-traditional CV risk factors
 Assess pharmacology of approved drugs, interactions, side effects in relation to cardiovascular and extracardiac complications
 Interpret biochemical and imaging assessments and appropriately refer for complete and thorough assessment
 Implement guidelines and protocols for diagnosis and management plans for non-traditional risk factors
 Select the appropriate investigations for refining non-traditional CV risk stratification
 Manage lifestyle changes, and pharmacological treatment
 Communicate with families, employers, other specialists, and general practitioners
 Motivate individuals to adopt healthier lifestyles, according to their special needs and preferences or health problems
Attitudes
 Adopt a non-judgemental attitude regarding the individual lifestyle
 Adopt a shared decision approach by actively engaging the patient in management decisions based on individual values, preferences, and associated con-
ditions and co-morbidities
 Adopt a culture of interdisciplinary teamwork
 Advocate for an integrated approach to chronic disease management, to include those with both traditional and non-traditional CV risk factors
 Advocate for patient education on primary prevention as an essential component of cardiac care
 Recognize the importance of primary and secondary prevention in individuals and patients with non-traditional CV risk factors
 Advocate for greater public awareness around non-traditional CV risk factors
Assessment tools
 MCQs
 Direct observation, workplace-based assessments (e.g. DOPS, mini-CEX, fieldnotes)
 Case-based discussions, entrustment-based discussions
 Multiple consultant reports
 Multi-source feedback
Level of Independence
 Level 4 (perform the activity under distant supervision. In this context this means to collaborate with experts of the clinical conditions associated with
elevated CV risk)
Related ESC guidelines and EAPC position papers
 Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur
Heart J 2018;39:3165–3241.
 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of
the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10
societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation
(EACPR). Eur Heart J 2016;37:2315–2381. Update 2021.
 Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the
auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of
Cardiology (ESC). Eur Heart J 2016;37:2768–2801.
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Description
Scope and timeframe:
All standard patients (outlined below) with an indication for a comprehensive CV prevention and rehabilitation programme
From referral to follow-up after a structured programme
Setting:
In-patient, out-patient, home based, community, virtual (including online and tele rehabilitation)
Including:
Management of patients with acute coronary syndromes, chronic coronary syndromes, after coronary artery bypass graft, valve, and large vessel surgery,
valve interventions, chronic heart failure, myocardial disease, congenital heart disease
Complete evaluation and risk stratification using appropriate tests
Lifestyle modification, through smoking cessation, nutritional, physical activity, and psycho-social counselling
Exercise prescription, exercise training structuring and supervision
Cardiorespiratory performance and interpretation
Guideline-directed medical therapy implementation
Behavioural change and self-management
Organization and optimization of a patient and family education programme
Organization of long-term follow-up
Excluding:
Patients with relevant comorbidities, cardiac implantable electrical devices (CIEDs), left ventricular assist devices (LVAD), heart transplantation (HTX) (see
Chapter 3.2)










 Outline indications for comprehensive CV prevention and rehabilitation
 Understand specific aspects of groups currently underrepresented in clinical studies (women, older people, ethnic minorities, migrants)
 Describe current evidence and expected benefits of comprehensive CV prevention and rehabilitation
 Consider appropriate referral and contraindication to comprehensive CV prevention and rehabilitation
 Outline the main core components of comprehensive CV prevention and rehabilitation programmes
 Discuss the global patient evaluation strategy
 Explain the different modalities of exercise
 Outline the principles of the FITT-VP (frequency, intensity, time, type, volume, progression) model for exercise prescription and of using scales of per-
ceived exertion (e.g. Borg)
 Discuss indications and interpretation of exercise capacity tests [ECG exercise testing, CPET, 6-min walk test (6MWT), strength tests]
 Outline indication and mechanisms of guideline-directed medical therapies
 Identify the interaction of pharmacological therapies with exercise
 Identify the principles of counselling for secondary prevention
 Describe psychological profiles and their impact on CV health
 Describe the patient education management (empowerment, self-management, self-efficacy, adherence promotion)
 Discuss the new technologies and their use for remote monitoring, programme delivery, and education
 Outline the composition and relationships of the interdisciplinary CV prevention and rehabilitation staff
 Outline the role of the family and social support for CVD patients
Skills
 Perform evaluation including CV risk factors, clinical condition, non-invasive assessment of CV functioning/disease, disabilities, nutrition, psycho-social
impact
Continued
Chapter 3: Secondary prevention and rehabilitation
3.1 Manage a prevention and rehabilitation programme for a cardiovascular patient
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 Explore patient expectations, values and priorities
 Perform and analyse exercise capacity tests [ECG exercise test, CPET, 6MWT, strength tests] for tailored exercise prescriptions
 Prescribe endurance continuous/interval training, resistance/strength training, balance training, and respiratory training
 Coordinate psychosocial, nutrition, and smoking cessation counselling and integrate results in clinical shared decision-making
 Optimize and up-titrate guideline-directed medical therapies, under consideration of effects on exercise tolerance
 Develop exercise training according to settings (residential, ambulatory, community-based, tele-monitoring), patient conditions (age, sex, psychology,
comorbidities), and preferences
 Assess nutritional habits and integrate into nutritional strategy
 Conceptualize, organize and drive an educational programme
 Organize a tele monitoring/tele-rehabilitation programme
 Manage comorbidities
 Recognize and treat emergency cases
 Manage patients with residual ischaemia (e.g. incomplete optimal revascularization, diffuse atherosclerotic disease)
 Detect post-interventional or post-surgical complications (e.g. early stent thrombosis or restenosis, pericardial tamponade)
 Apply effective communication and behavioural change techniques (e.g. motivational interviewing for smoking cessation and patient education)
 Organize the follow-up, links with general practitioners and/or cardiologists, and other health professionals
Attitudes
 Adopt a non-judgemental attitude regarding individual lifestyle choices
 Be aware of the influence of CV risk factors and diseases in patient prognosis (differentiate mortality and morbidity) and quality of life
 Be aware of the importance of CV prevention and rehabilitation in the pathway and care delivery of the CV patient
 Work in interdisciplinary teams with health professionals involved in secondary prevention
 Deliver education, empathy and encouragement to the patient to reduce their CV risk factors with help of all the professional resources
 Educate patients on how his/her entourage can support prevention
 Support patients with genetic disorders (psychological counselling, explain consequences for disease management and for relatives)
 Motivate patient to sustain long term adherence with lifestyle, exercise training, and medical therapy
 Actively involve the patient in shared decision-making to promote optimal self-management and long-term adherence to behaviour change
 Advocate comprehensive CV prevention and rehabilitation programmes to include all high-risk patients
Assessment tools
 MCQs
 Direct observation, workplace-based assessments (e.g. DOPS, mini-CEX, fieldnotes)
 Case-based discussions, entrustment-based discussions
 Multiple consultant reports
 Multi-source feedback
Level of independence
 Level 5 (perform the activity without supervision, teach and supervise others)
Related ESC guidelines and EAPC position papers
 Ambrosetti M, Abreu A, Corra U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation.
2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J
Prev Cardiol 2020;doi:10.1177/2047487320913379.
 Abreu A, Frederix I, Dendale P, et al. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation pro-
grammes in Europe: The avenue towards EAPC accreditation programme: a position statement of the Secondary Prevention and Rehabilitation Section
of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;doi:10.1177/2047487320924912.
 Scherrenberg M, Wilhelm M, Hansen D, et al. The future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic from the sec-
ondary prevention and rehabilitation section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;doi:10.1177/
2047487320939671.
 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of
the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10
societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation
(EACPR). Eur Heart J 2016;37:2315–2381. Update in 2021.
 Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the
European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and
the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol 2013;20:442–467.
 Piepoli MF, Conraads V, Corra U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association
and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 2011;13:347–357.
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Description
Scope and timeframe:
All complex patients (outlined below) with an indication for a comprehensive CV prevention and rehabilitation programme
From referral to follow-up after a structured programme
Setting:
In-patient, out-patient, home based, community, virtual (including online and tele rehabilitation)
Including:
Management of patients with stroke, peripheral artery occlusive disease (PAOD, including amputation), diabetes, chronic kidney disease, chronic obstructive
pulmonary disease, rheumatologic disease, orthopaedic disease, and frailty
Management of CIED, LVAD, and HTX patients
Patient global evaluation and risk stratification using appropriate tests
Lifestyle modification, through nutritional, physical activity and psycho-social counselling
Adapted exercise prescription, adapted exercise training structuring and supervision
Cardiorespiratory performance and interpretation (identifying those patients who cannot do it)
Guideline-directed medical therapy implementation
Behavioural change and self-management
Organization and optimization of a patient education programme, including specific information related to the comorbidity
Organization of long-term follow-up
Excluding:










 Discuss the management of individual comorbidities: stroke, PAOD, diabetes, chronic kidney disease, chronic obstructive pulmonary disease, rheumato-
logic disease, orthopaedic disease, and frailty
 Discuss the management of CIED, LVAD, and HTX patients
 Describe the current evidence and expected benefits of comprehensive CV prevention and rehabilitation
 Consider appropriate referral and contraindication to comprehensive CV prevention and rehabilitation programmes
 Outline the main core components of comprehensive CV prevention and rehabilitation programmes
 Discuss the global patient evaluation strategy
 Identify the interaction between pharmacological and CIED therapies with exercise
 Explain the different modalities of exercise and how to adapt to specific comorbidities, and frailty
 Outline the principles of the FITT-VP (frequency, intensity, time, type, volume, progression) model for exercise prescription and of using scales of per-
ceived exertion (e.g. Borg)
 Discuss indications and interpretation of exercise capacity tests (ECG exercise testing, CPET, 6MWT, strength tests)
 Know key frailty tests (i.e. timed up and go, walking speed test) and tests for cognitive deficits (mini-mental status test)
 Identify the principles of counselling for secondary prevention, specifically including management linked to comorbidities
 Describe psychological profiles and their impact on CV health
 Describe the patient education management (empowerment, self-management, self-efficacy, adherence promotion)
 Discuss the new technologies and their use for remote monitoring, programme delivery, and education
 Outline the composition of and relationships between the interdisciplinary CV prevention and rehabilitation staff
 Discuss how comorbidities influence CV prevention and rehabilitation delivery and need for adaptation
 Discuss the influence of CV risk factors and diseases in patient prognosis (differentiate mortality and morbidity) and quality of life
 Outline the importance of comprehensive CV prevention and rehabilitation in the pathway and care delivery of the CV patient without and with
comorbidities
Continued
3.2 Manage a prevention and rehabilitation programme for a cardiovascular patient
with significant comorbidities, frailty, and/or cardiac devices
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Continued
Skills
 Manage specific aspects of individual comorbidities: stroke, PAOD, diabetes, chronic kidney disease, chronic obstructive pulmonary disease, rheumato-
logic disease, orthopaedic disease, and frailty
 Manage specific aspects of CIED, LVAD and heart transplant patients
 Perform evaluation including CV risk factors, clinical condition, non-invasive assessment of CV functioning/disease, disabilities, nutrition, psycho-social
impact
 Explore patient expectations, values and priorities
 Perform and interpret exercise capacity tests (ECG exercise testing, CPET, 6MWT, strength tests) for tailored exercise prescriptions
 Prescribe endurance continuous/interval training, resistance/strength training, and respiratory training
 Develop exercise training according to settings (residential, ambulatory, community-based, tele-monitoring), patient conditions (age, sex, comorbidities,
psychologic status), and preferences
 Conceptualize, organize and drive an educational programme with specificities to the different comorbidities
 Organize a tele-monitoring/tele-rehabilitation programme
 Optimize and up-titrate guideline-directed medical therapies, adapted to the exercise tolerance and comorbidities
 Identify and analyse CIED functioning at rest and during effort
 Manage comorbidities under consideration of possible drug interactions and contraindications
 Recognize and treat emergency cases related to comorbidities or devices
 Manage patients with residual ischaemia (e.g. incomplete optimal revascularization, diffuse atherosclerotic disease)
 Detect post-interventional or post-surgical complications (e.g. early stent thrombosis or restenosis, pericardial tamponade)
 Apply effective communication and behavioural change techniques (e.g. motivational interviewing for smoking cessation and patient education)
 Make end of life discussions possible for terminal patients
 Organize the follow-up, links with general practitioners and/or cardiologists, and other health professionals
Attitudes
 Work with interdisciplinary teams of health professionals involved in secondary prevention and rehabilitation
 Educate and encourage patients to reduce their CV risk factors with help of all the professional resources
 Educate patients on how his/her entourage can support prevention
 Support patients with genetic disorders (psychological counselling, explain consequences for disease management and for relatives)
 Motivate patients to sustain long-term adherence with lifestyle, exercise training, and medical therapy, despite their comorbidities
 Actively involve patients in shared decision-making to promote optimal self-management and long term adherence to behaviour change
 Advocate for comprehensive CV prevention and rehabilitation programmes to improve referral and uptake
Assessment tools
 MCQs
 Direct observation, workplace-based assessments (e.g. DOPS, mini-CEX, fieldnotes)
 Case-based discussions, entrustment-based discussions
 Multiple consultant reports
 Multi-source feedback
Level of independence
 Level 5 (perform the activity without supervision, teach and supervise others)
Related ESC guidelines and EAPC position papers
 Pedretti RF, Iliou MC, Israel CW et al. Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices recipients.
A consensus document from the European Association of Preventive Cardiology (EAPC; Section on Secondary Prevention and Rehabilitation) and
European Heart Rhythm Association (EHRA). Eur J Prev Cardiol 2020;doi:10.1093/eurjpc/zwaa121.
 Ambrosetti M, Abreu A, Corra U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation.
2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J
Prev Cardiol 2020;doi:10.1177/2047487320913379.
 Abreu A, Frederix I, Dendale P, et al. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation pro-
grammes in Europe: the avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section
of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;doi:10.1177/2047487320924912.
 Scherrenberg M, Wilhelm M, Hansen D, et al. The future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic from the sec-
ondary prevention and rehabilitation section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;doi:10.1177/
2047487320939671.
 Hansen D, Kraenkel N, Kemps H, et al. Management of patients with type 2 diabetes in cardiovascular rehabilitation. Eur J Prev Cardiol 2019;26:133–144.
 Kemps H, Krankel N, Dorr M, et al. Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A
Position Paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2019;26:709–727.
Continued
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Continued
 Vigorito C, Abreu A, Ambrosetti M, Belardinelli R, Corra U, Cupples M, Davos CH, Hoefer S, Iliou MC, Schmid JP, Voeller H, Doherty P. Frailty and car-
diac rehabilitation: A call to action from the EAPC Cardiac Rehabilitation Section. Eur J Prev Cardiol 2017;24:577–590.
 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of
the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10
societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation
(EACPR). Eur Heart J 2016;37:2315–2381. Update in 2021.
 Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the
European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and
the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol 2013;20:442–467.
 Piepoli MF, Conraads V, Corra U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association
and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 2011;13:347–357.
Description
Scope and timeframe:
Cancer patients, in particular after cardiotoxic cancer therapy, from cancer diagnosis to follow-up surveillance
Setting:
In-patient, out-patient, home based, community, virtual (including online and tele rehabilitation)
Including:
Assessment of the clinical status, identification of risk factors for CVD and cancer, using basic and advanced tools for investigation; pharmacological and non-
pharmacological treatment
Excluding:










 Identify clinical interactions between cancer and CVDs
 Identify risk factors common to cancer and CVD (e.g. ageing, smoking, alcohol abuse, unbalanced diet and physical inactivity)
 Describe CV toxicity of specific chemo- and radiotherapies in cancer patients undergoing treatment as well as cancer survivors and its influence on exer-
cise capacity and quality of life
 Describe the prognosis of different cancers
 Discuss the specific rehabilitation needs of cancer patients with or at risk of CVD (exercise, psychological, prevention, social, education)
 Describe the role of exercise in cardio-oncology rehabilitation to minimize the negative effects of cancer therapies (e.g. cardio-toxicity, fatigue, bone
loss, lymphoedema, autonomic dysfunction, depression, anxiety)
 Discuss indications and interpretation of exercise capacity tests (ECG exercise testing, CPET, 6MWT, strength tests)
 Describe the role of exercise and cardio-oncology rehabilitation to limit cancer progression and relapses
 Discuss the strategies to limit disabilities, impaired quality of life and psychosocial distress induced by cancer and CVD
Skills
 Differentiate cardio-oncology rehabilitation in cancer patients from conventional oncology rehabilitation
 Identify cancer patients with expected greater benefits from cardio-oncology rehabilitation
 Adapt comprehensive cardio-oncology rehabilitation to the cancer situation (active cancer or cancer survivors)
 Perform and interpret exercise capacity tests (ECG exercise testing, CPET, 6MWT, strength tests) for tailored exercise prescriptions
 Interpret imaging investigations performed in oncology patients and derive prognostic information
Continued
3.3 Manage a cardiovascular prevention and rehabilitation programme for an oncology
patient
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 Identify the appropriate cardio-oncology rehabilitation setting (residential, out-patients, centre-based, community-based, home-based) according to
patient’s preferences and possibilities
 Review cancer history, cancer therapies and related side effects, drug interactions
 Evaluate the risk of CVD in active cancer and cancer survivors
 Establish goals for risk factors control modulated by the presence or history of cancer
 Select the appropriate method of functional testing in cancer patients
 Evaluate and treat cancer-related cachexia, sarcopenia and anaemia
 Adapt type and intensity of training to cancer localization, cancer stages and specific sequelae (e.g. appropriate intensity in case of cachexia or frailty, role
of upper body strength training in breast cancer, role of inspiratory muscle training in thoracic cancer)
 Interdisciplinary work with the oncology team, and other healthcare professionals
 Make end of life discussions possible for terminal patients
 Provide view/opinion about return to work
Attitudes
 Aim to decrease the risk of CVD in cancer patients
 Consider cardio-oncology rehabilitation as a standard of care for cancer patients and survivors at high risk for CVD
 Deal optimistically with cancer
 Collaborate with oncologists and other care providers in the field of oncology
 Reassure and motivate cancer patients
Assessment tools
 MCQs
 Direct observation, workplace-based assessments (e.g. DOPS, mini-CEX, fieldnotes)
 Case-based discussions, entrustment-based discussions
 Multiple consultant reports
 Multi-source feedback
Level of Independence
 Level 5 (perform the activity without supervision, teach and supervise others)
Related ESC guidelines and EAPC position papers
 Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the
auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of
Cardiology (ESC). Eur Heart J 2016;37:2768–2801.
Related AHA Scientific Statement
 Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific
statement from the American Heart Association. Circulation 2019;139:e997–e1012.
Description
Scope and timeframe:




Evaluation of personal and family history (including habitual physical activity level, sport type, fitness), physical examination, blood pressure measurement, 12-
lead ECG, further testing (ambulatory ECG monitoring, echocardiography, advanced imaging, exercise testing, CPET), if appropriate
Identification of potential high-risk athletes for sudden cardiac death and for other CV conditions that may worsen because of intensive athletic training
Excluding:






Chapter 4: Sports cardiology and exercise
4.1 Manage pre-participation evaluation in a competitive athlete














 Describe physiological adaptations to acute and chronic exercise
 Describe physiological adaptations in different situations such as deep sea, high altitude, low or high temperatures
 Assess the type of practiced sport (skill, power, mixed, endurance), the specific metabolic features and induced CV remodelling
 Describe the physiological CV adaptation induced by regular exercise and the normal vs. borderline ECG findings in athletes
 Describe the incidence of sudden cardiac death in athletes and the most frequent and emergent CV conditions involved
 Describe CV conditions that may worsen because of intensive athletic training and those that will benefit from primary prevention
 Describe how to establish a diagnostic flowchart for sudden death prevention in the presence of abnormal findings (including ECG and physical examin-
ation findings) during pre-participation evaluation (PPE) in athletes
 Describe indications for cardiac multi-modality imaging and genetic testing in PPE
 Discuss the CV effects of the main doping substances
Skills
 Obtain a relevant history and perform an appropriate physical examination, including habitual physical activity level and sport type (skill, power, mixed,
endurance)
 Evaluate the CV risk profile based on appropriate risk calculators and the fitness level of an athlete over 35 years of age and the burden of risk factors
for CVD
 Understand the results of physical examination and 12-lead ECG showing physiological, borderline or pathological findings
 Identify the potential high-risk athletes and further evaluate the risk of sudden cardiac death or acceleration of an inherited predisposition or exacerba-
tion of cardiac damage due to intercurrent illness resulting from intense and prolonged exercise.
 Evaluate potential doping issues and substance abuse
 Choose the appropriate screening modality in the presence of abnormal findings (e.g. ECG exercise test, CPET, echocardiography, ambulatory ECG
monitoring, cardiac computed tomography angiography, cardiac magnetic resonance, genetic testing)
 Perform and interpret ECG exercise test, CPET, echocardiography, ambulatory ECG monitoring if indicated
 Integrate results from advanced CV imaging and genetic testing in clinical decision-making
 Advise regarding exercise and exercise training in athletes with cardiac disease according to history, clinical finding, diagnostics and CPET
Attitudes
 Adopt a non-judgemental attitude to an athlete regarding her/his lifestyle or referred symptoms, if any
 Communicate with the athlete, family, and the team physician to optimize the management of potentially abnormal findings during PPE and how this may
affect sports eligibility
 Communicate concepts of exercise and exercise programme with the athlete
 Motivate the athlete to systematically undergo PPE and explain the cost-effectiveness consideration of this model
Assessment tools
 MCQs
 Direct observation, workplace-based assessments (e.g. DOPS, mini-CEX, fieldnotes)
 Case-based discussions, entrustment-based discussions
 Multiple consultant reports
 Multi-source feedback
Level of independence
 Level 5 (perform the activity without supervision, teach and supervise others)
Related ESC guidelines and EAPC position papers
 Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J
2020;doi:10.1093/eurheartj/ehaa605.
 Budts W, Pieles GE, Roos-Hesselink JW, et al. Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital
Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the European Association of Preventive Cardiology (EAPC),
the European Society of Cardiology (ESC) Working Group on Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and
Prevention Working Group of the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2020;doi:10.1093/eurheartj/
ehaa501.
 Heidbuchel H, Adami PE, Antz M, et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with
arrhythmias and potentially arrhythmogenic conditions: Part 1: Supraventricular arrhythmias. A position statement of the Section of Sports Cardiology
and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA), both associations
of the European Society of Cardiology. Eur J Prev Cardiol 2020;doi:10.1177/2047487320925635.
Continued
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 Heidbuchel H, Arbelo E, D’Ascenzi F, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with
arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace
2020;doi:10.1093/europace/euaa106.
 Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies,
myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur
Heart J 2019;40:19–33.
 Borjesson M, Dellborg M, Niebauer J, et al. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary
artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J
2019;40:13–18.
 Niebauer J, Borjesson M, Carre F, et al. Recommendations for participation in competitive sports of athletes with arterial hypertension: a position state-
ment from the sports cardiology section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2018;39:3664–3671.
 Mont L, Pelliccia A, Sharma S, et al. Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the
EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace 2017;19:139–163.
Description
Scope and timeframe:
Leisure-time and competitive athletes, from the time the athlete with suspected or known CVD self-refers or is referred for a consultation until regular fol-
low-up
Setting:
Most commonly out-patient setting, but also in-patient setting and emergency department
Including:
Assessment with history, physical examination, basic and advanced tools for investigation, differentiation of physiological adaptation to exercise from pheno-
types of CVD, identification of risk factors for sudden cardiac death and high-risk conditions, recommendation of lifestyle and pharmacological treatment,
exercise prescription and counselling on leisure-time and competitive sports
Excluding:










 Describe phenotypes of physiological adaptation to exercise
 Recognize the challenges of differentiating athlete’s heart from heart disease
 Identify risk factors for sudden cardiac death and high-risk conditions
 Outline non-pharmacological and pharmacological treatment of athletes with common CV conditions
 Outline exercise recommendations in athletes with CVD
 Recognize the ethical and legal considerations of disqualification from competitive sports participation
Skills
 Obtain a focused history and perform appropriate physical examination
 Propose and perform appropriate non-invasive, first-line clinical investigations (12-lead ECG, transthoracic echocardiogram, exercise testing/CPET, ECG
monitor) to assess athletes with suspected or known cardiac disease
 Propose further appropriate advanced investigations, including genetic testing
 Integrate the results in an interdisciplinary setting
 Illustrate how risk stratification of athletes with CVD informs their management
 Prescribe tailored exercise recommendations based on CPET
 Implement recommendations for exercise prescription and eligibility for participation in competitive sport in athletes with cardiac disease
 Prescribe comprehensive CV prevention and rehabilitation for athletes with CVD, if indicated, and adopt programmes appropriately
Continued
4.2 Manage the work-up of an athlete with suspected or known cardiovascular disease
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Attitudes
 Integrate the results of investigations in an interdisciplinary setting
 Communicate effectively results and exercise recommendations to the athletes, team doctors, coaches, families
 Promote a shared-decision-making model, particularly in conditions with limited evidence relating to the risk of exercise
 Adopt a holistic approach to the impact of exercise restriction and disqualification from competitive sports on an athlete, in terms of psychological, phys-
ical, and financial wellbeing
Assessment tools
 MCQs
 Direct observation, workplace-based assessments (e.g. DOPS, mini-CEX, fieldnotes)
 Case-based discussions, entrustment-based discussions
 Multiple consultant reports
 Multi-source feedback
Level of independence
 Level 4 (perform the activity under distant supervision. In this context this means to work in a network with dedicated sports cardiology referral centres
in complicated cases)
Related ESC guidelines and EAPC position papers
 Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J
2020;doi:10.1093/eurheartj/ehaa605.
 Budts W, Pieles GE, Roos-Hesselink JW, et al. Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital
Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the European Association of Preventive Cardiology (EAPC),
the European Society of Cardiology (ESC) Working Group on Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and
Prevention Working Group of the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2020;doi:10.1093/eurheartj/
ehaa501.
 Heidbuchel H, Adami PE, Antz M, et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with
arrhythmias and potentially arrhythmogenic conditions: Part 1: Supraventricular arrhythmias. A position statement of the Section of Sports Cardiology
and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA), both associations
of the European Society of Cardiology. Eur J Prev Cardiol 2020;doi:10.1177/2047487320925635.
 Heidbuchel H, Arbelo E, D’Ascenzi F, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with
arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace
2020;doi:10.1093/europace/euaa106.
 Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies,
myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur
Heart J 2019;40:19–33.
 Borjesson M, Dellborg M, Niebauer J, et al. Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary
artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J
2019;40:13–18.
 Niebauer J, Borjesson M, Carre F, et al. Recommendations for participation in competitive sports of athletes with arterial hypertension: a position state-
ment from the sports cardiology section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2018;39:3664–3671.
Description
Scope and timeframe:
Healthy individuals, athletes, individuals with CVD risk factors, and CVD patients. From indication for using CPET until communicating the results
Setting:
In-patient, out-patient, exercise physiology laboratory, on field
Including:
Performing a comprehensive CPET on a bicycle or treadmill, or other types of ergometers, or using mobile devices under real-life conditions (i.e. patient’s
workplace, athlete on the field), with and without invasive measurements, interpreting and reporting the results
Excluding:
Complex cases with a predominant pulmonary problem which should be managed in cooperation with a pulmonary specialist
Continued
Chapter 5: Cardiopulmonary exercise testing
5.1 Use cardiopulmonary exercise testing for diagnosis, risk stratification and exercise
prescription
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41. Tanner FC, Brooks N, Fox KF, Gonçalves L, Kearney P, Michalis L, Pasquet A,
Price S, Bonnefoy E, Westwood M, Plummer C, Kirchhof P; ESC Scientific
Document Group. ESC core curriculum for the cardiologist. Eur Heart J 2020;41:
3605–3692.
42. Frank JR, Snell L, Sherbino J. CanMEDS 2015 Physician Competency Framework.
Royal College of Physicians and Surgeons of Canada 2015. http://canmeds.royal
college.ca/en/framework (last accessed November 4th 2020).
43. Ross RD, Brook M, Feinstein JA, Koenig P, Lang P, Spicer R, Vincent JA, Lewis
AB, Martin GR, Bartz PJ, Fischbach PS, Fulton DR, Matherne GP, Reinking B,
Srivastava S, Printz B, Geva T, Shirali GS, Weinberg P, Wong PC, Armsby LB,
Vincent RN, Foerster SR, Holzer RJ, Moore JW, Marshall AC, Latson L, Dubin
AM, Walsh EP, Franklin W, Kanter RJ, Saul JP, Shah MJ, Van Hare GF, Feltes TF,
Roth SJ, Almodovar MC, Andropoulos DB, Bohn DJ, Costello JM, Gajarski RJ,
Mott AR, Stout K, Valente AM, Cook S, Gurvitz M, Saidi A, Webber SA, Hsu
DT, Ivy DD, Kulik TJ, Pahl E, Rosenthal DN, Morrow R, Mahle WT, Murphy AM,
Li JS, Law YM, Newburger JW, Daniels SR, Bernstein D, Marino BS. 2015
SPCTPD/ACC/AAP/AHA training guidelines for pediatric cardiology fellowship
programs. J Am Coll Cardiol 2015;doi:10.1016/j.jacc.2015.03.004.
44. ESC Preventive Cardiology Textbooks. https://www.escardio.org/Education/
Textbooks/prevention-and-rehabilitation (last accessed Novemeber 4th 2020).








niversidade de Lisboa user on 22 April 2021
